Mode
Text Size
Log in / Sign up
N/A N=97 Treatment

WaveLight® Refractive Myopic Study

Refractive Error

Enrolled (actual)
97
Serious AEs
1.0%
Results posted
Mar 2015
Primary outcome: Primary: Least Squares Mean Difference in Binocular UCVA at 1 Month Post-Treatment and Pre-Treatment Binocular BCVA — -0.0519 logMAR

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Wavelight® Refractive Suite (Device); LASIK surgery (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Alcon Research
Primary completion
Jan 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Least Squares Mean Difference in Binocular UCVA at 1 Month Post-Treatment and Pre-Treatment Binocular BCVA
-0.0519
SECONDARY
Mean Difference Between Achieved and Target Corneal Flap Thickness as Assessed by OCT
3.958; 3.448; 3.200; 3.905; 3.427; 2.253
SECONDARY
Mean Manifest Refraction (Sphere)
-3.672; 0.046; 0.077; 0.046; 0.017
SECONDARY
Mean Manifest Refraction (Cylinder)
-0.32; -0.16; -0.16; -0.18
SECONDARY
Mean Laser Treatment Time
9.912; 30.161; 9.709; 29.214
SECONDARY
Mean Total Laser Treatment Time
40.073; 38.923; 78.996
SECONDARY
Mean Response: "Rate Your Vision, Over the Past 4 Weeks, With NO Glasses or Contact Lenses"
3.6; 9.1; 9.4
SECONDARY
Percent Response by Category: "In the Past 4 Weeks, to See Far Away, I Wore..."
36.5; 1.0; 0.0; 32.3; 0.0; 0.0
SECONDARY
Percent Response by Category: "I Worry About my Vision"
10.4; 21.9; 52.6; 30.2; 51.0; 33.7
SECONDARY
Percent Response by Category: "My Vision Is a Concern in My Daily Life"
6.3; 27.1; 63.2; 34.4; 51.0; 27.4
SECONDARY
Percent Response by Category: "Driving at Night"
4.2; 100.0; 100.0; 38.5; 0.0; 0.0
SECONDARY
Mean Contrast Sensitivity (CS)
0.768; 1.845; 1.868; 1.894; 1.898; 0.937
SECONDARY
Wavefront Aberrometry
0.7; 0.5; 0.7; 0.5; 0.1; 0.2
SECONDARY
Corneal Curvature as Measured by Keratometry
43.5; 40.4; 40.6; 40.6; 43.5; 40.4

Summary

The purpose of this study is to evaluate outcomes of subjects undergoing myopic surgery using the WaveLight® Refractive Suite (Excimer EX500 and Femtosecond FS200 lasers).

Eligibility Criteria

Inclusion Criteria

  • Willing and able to understand and sign an informed consent form.
  • Have refractive error (in both eyes) that requires refractive surgery.
  • Willing to undergo LASIK surgery using the Wavelight® Refractive Suite.
  • Myopia between 0.00 to -12.0 diopters pre-operatively.
  • Astigmatism between 0.00 to +6.00 diopters pre-operatively.
  • Willing and able to attend post-operative examinations per protocol schedule.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • Participation in a clinical study within the last 30 days.
  • History of previous corneal surgery in either eye.
  • Multifocal ablations in either eye.
  • PRK or PTK surgery in either eye.
  • Suffering from acute or recurring eye diseases in either eye, such as corneal ulcers, cataract, etc.
  • Any ocular disease and/or condition that, in the Investigator's clinical judgment, may put subject at significant risk, compromise study results, or interfere significantly with subject's participation in the study.
  • Unable to discontinue contact lens wear as specified in protocol.
  • History of Herpes simplex or Herpes zoster keratitis.
  • Active ocular rosacea.
  • Lyme disease.
  • History of dry eye that is unresponsive to treatment.
  • Severe ocular allergies.
  • Other medical conditions and use of medications as specified in protocol.
  • Pregnant or planning to become pregnant during the study.
  • Other protocol-specified exclusion criteria may apply.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01941498). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search